Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LTG 001

Next Previous
Drug Profile

LTG 001

Alternative Names: LTG-001

Latest Information Update: 25 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Latigo Biotherapeutics
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action Nav1.8 voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative pain
  • Phase I Acute pain

Most Recent Events

  • 07 Jan 2026 Latigo Biotherapeutics completes a phase-II trial for Postoperative pain in USA (PO) (NCT07102459)
  • 17 Nov 2025 Latigo Biotherapeutics completes a phase I trial for Pain (In volunteers) in USA (PO) (NCT07341152)
  • 01 Oct 2025 Latigo Biotherapeutics plans a phase II trial for Pain in Denmark (PO, Tablet), in October 2025 (CTIS2025-522755-26-01; LTG-001-015)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top